Impact Factor 3.519
2017 JCR, Clarivate Analytics 2018

Frontiers journals are at the top of citation and impact metrics

This article is part of the Research Topic

Follicle-Stimulating Hormone: Beyond Fertility

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Endocrinol. | doi: 10.3389/fendo.2019.00398

Pharmacogenetics of FSH action in the female

 Alessandro Conforti1*,  Alberto Vaiarelli2,  Danilo Cimadomo2, Francesca Bagnulo1, Stefania Peluso1,  Francesca Di Rella3,  Luigi Carbone1,  Filippo M. Ubaldi2, Giuseppe De Placido1, Ilpo Huhthaniemi4 and  Carlo Alviggi1
  • 1University of Naples Federico II, Italy
  • 2GENERA reparto di PMA della Clinica Valle Giulia, Italy
  • 3National Cancer Institute G. Pascale Foundation (IRCCS), Italy
  • 4Imperial College London, United Kingdom

The purpose of a pharmacogenomic approach is to tailor treatment on the basis of individual human genotype. This strategy is becoming increasingly common in medicine, and important results have been obtained in oncologic and antimicrobial therapies. The rapid technological developments and availability of innovative methodologies have revealed the existence of numerous genotypes that can influence the action of medications, and that a true “individualized” approach could become in the future a reality in clinical practice. Moreover, comparing with the past, genotype analyses are now more easily available at accessible cost.
Concerning human reproduction, there is ample evidence that several variants of gonadotropins and their receptors influence female reproductive health and ovarian response to exogenous gonadotropins. In more detail, variants in genes of follicle-stimulating hormone β-chain (FSH-B) and its receptor (FSH-R) seem to be the most promising candidates for a pharmacogenomic approach to controlled ovarian stimulation in assisted reproductive technologies.
In the present review, we summarize the evidence regarding FSH-B and FSH-R variants, with special reference to their impact on reproductive health and assisted reproductive technology treatments.

Keywords: FSH, FSH receptor (FSHR), polymorphisms, mutations, ovarian stimulation, Assisted Reproductive Technology, IVF, Female infertility

Received: 16 Mar 2019; Accepted: 05 Jun 2019.

Edited by:

Sandro C. Esteves, Androfert, Andrology and Human Reproduction Clinic, Brazil

Reviewed by:

Bianca Bianco, Faculdade de Medicina do ABC, Brazil
Giulia Brigante, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy  

Copyright: © 2019 Conforti, Vaiarelli, Cimadomo, Bagnulo, Peluso, Di Rella, Carbone, Ubaldi, De Placido, Huhthaniemi and Alviggi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Alessandro Conforti, University of Naples Federico II, Napoli, Italy,